Kleder (Lenalidomide)

Lenalidomide binds to the cereblon protein within the CRL4‑CRBN ubiquitin ligase complex, causing selective degradation of the transcription factors Ikaros and Aiolos. This action modulates immune cell activity, inhibits new blood‑vessel formation, and triggers programmed cell death in malignant plasma cells.

The specific dose of Kleder is determined individually by the prescribing physician based on the patient’s diagnosis, disease stage, renal function and prior therapies. Only a qualified healthcare professional can set the appropriate dosing regimen.

Lenalidomide is classified as Pregnancy Category X because it can cause severe fetal harm. It is contraindicated in pregnancy, and both male and female patients of reproductive potential must use effective contraception. Breastfeeding is not recommended while on treatment.

To request Kleder, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kleder (lenalidomide) belongs to the immunomodulatory drug class, offering a distinct mechanism from proteasome inhibitors or monoclonal antibodies. It provides oral administration, anti‑angiogenic effects and immune activation, making it a valuable option especially in relapsed or refractory disease settings.

Kleder should be stored at or below 25 °C in its original container, protected from moisture and direct sunlight. Do not store in a bathroom or near heat sources, and keep the product out of reach of children.

Kleder is taken orally, usually with or without food as directed by the prescriber. The tablets are swallowed whole with a glass of water and should be taken at the same time each day to maintain consistent drug levels.

The most serious risks include severe neutropenia leading to infection, venous thromboembolism, secondary primary malignancies, hepatotoxicity, severe skin reactions such as Stevens‑Johnson syndrome, and embryofetal toxicity. Patients should be monitored closely for these events.

Kleder is contraindicated in patients who are pregnant, those who cannot use effective contraception, individuals with known hypersensitivity to lenalidomide or any component of the formulation, and patients with uncontrolled severe infections or active thromboembolic disease without appropriate prophylaxis.